RU2625315C2 - Производные 8-карбамоил-2-(2,3-дизамещенного пирид-6-ил)-1,2,3,4-тетрагидроизохинолина в качестве индуцирующих апоптоз средств для лечения рака - Google Patents
Производные 8-карбамоил-2-(2,3-дизамещенного пирид-6-ил)-1,2,3,4-тетрагидроизохинолина в качестве индуцирующих апоптоз средств для лечения рака Download PDFInfo
- Publication number
- RU2625315C2 RU2625315C2 RU2014119250A RU2014119250A RU2625315C2 RU 2625315 C2 RU2625315 C2 RU 2625315C2 RU 2014119250 A RU2014119250 A RU 2014119250A RU 2014119250 A RU2014119250 A RU 2014119250A RU 2625315 C2 RU2625315 C2 RU 2625315C2
- Authority
- RU
- Russia
- Prior art keywords
- methyl
- pyridin
- dec
- ylcarbamoyl
- benzothiazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547162P | 2011-10-14 | 2011-10-14 | |
| US61/547,162 | 2011-10-14 | ||
| CNPCT/CN2012/079012 | 2012-07-23 | ||
| CN2012079012 | 2012-07-23 | ||
| PCT/US2012/059720 WO2013055897A1 (en) | 2011-10-14 | 2012-10-11 | 8 - carbamoyl - 2 - (2,3- di substituted pyrid - 6 - yl) -1,2,3,4 -tetrahydroisoquinoline derivatives as apoptosis - inducing agents for the treatment of cancer and immune and autoimmune diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014119250A RU2014119250A (ru) | 2015-11-20 |
| RU2625315C2 true RU2625315C2 (ru) | 2017-07-13 |
Family
ID=47116421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014119250A RU2625315C2 (ru) | 2011-10-14 | 2012-10-11 | Производные 8-карбамоил-2-(2,3-дизамещенного пирид-6-ил)-1,2,3,4-тетрагидроизохинолина в качестве индуцирующих апоптоз средств для лечения рака |
Country Status (36)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2857201C2 (ru) * | 2020-06-01 | 2026-02-27 | Виген Биомедисн Текнолоджи (Шанхай) Ко., Лтд. | Новое соединение пиразина |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI561521B (en) | 2011-10-14 | 2016-12-11 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8889675B2 (en) | 2011-10-14 | 2014-11-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20160158377A1 (en) * | 2014-12-09 | 2016-06-09 | Abbvie Inc. | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same |
| CA2969908A1 (en) * | 2014-12-09 | 2016-06-16 | Abbvie Inc. | Antibody drug conjugates with cell permeable bcl-xl inhibitors |
| CN111620861A (zh) * | 2014-12-09 | 2020-09-04 | 艾伯维公司 | 具有低细胞渗透性的bcl-xl抑制性化合物以及包括它的抗体药物缀合物 |
| CN104473923B (zh) * | 2014-12-29 | 2016-08-17 | 巩春智 | 一种防治慢性心力衰竭的药物组合物及其应用 |
| WO2016131100A1 (en) * | 2015-02-18 | 2016-08-25 | The Walter And Eliza Hall Institute Of Medical Research | Methods of treating infectious diseases |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| WO2017214458A2 (en) * | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| JP2019521114A (ja) * | 2016-06-08 | 2019-07-25 | アッヴィ・インコーポレイテッド | 抗ｅｇｆｒ抗体薬物コンジュゲート |
| AU2017277534A1 (en) * | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-EGFR antibody drug conjugates |
| TW202320860A (zh) * | 2016-06-08 | 2023-06-01 | 美商艾伯維有限公司 | 抗egfr抗體藥物結合物 |
| EP3468598A1 (en) * | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| TWI762487B (zh) * | 2016-06-08 | 2022-05-01 | 美商艾伯維有限公司 | 抗-b7-h3抗體及抗體藥物結合物 |
| EP3468596A2 (en) * | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| WO2018092064A1 (en) * | 2016-11-18 | 2018-05-24 | Novartis Ag | Combinations of mdm2 inhibitors and bcl-xl inhibitors |
| WO2019000236A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| TW202002952A (zh) | 2018-03-15 | 2020-01-16 | 美商艾伯維有限公司 | 用於治療胰臟癌之abbv-621與抗癌劑之組合 |
| AR119494A1 (es) * | 2019-07-29 | 2021-12-22 | Servier Lab | DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS |
| AU2021386367A1 (en) | 2020-11-24 | 2023-06-22 | Les Laboratoires Servier | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| KR20230170644A (ko) | 2021-02-02 | 2023-12-19 | 르 라보레또레 쎄르비에르 | 선택적 bcl-xl protac 화합물 및 사용 방법 |
| PE20250007A1 (es) * | 2022-05-06 | 2025-01-07 | Treeline Biosciences Inc | Degradadores bcl-xl-heterobifuncionales de tetrahidroisoquinolina |
| AU2023264537A1 (en) * | 2022-05-06 | 2024-11-14 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| PE20251072A1 (es) | 2022-05-20 | 2025-04-10 | Novartis Ag | Conjugados de anticuerpo-farmaco de compuestos antineoplasicos y metodos de uso de los mismos |
| EP4525926A1 (en) | 2022-05-20 | 2025-03-26 | Novartis AG | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| JP2025517430A (ja) | 2022-05-20 | 2025-06-05 | ノバルティス アーゲー | Ｅｐｈａ２ ｂｃｌ－ｘｌ阻害剤抗体－薬物コンジュゲートおよびその使用の方法 |
| CN119278203A (zh) * | 2022-06-10 | 2025-01-07 | 成都先导药物开发股份有限公司 | 一种化合物及其在制备bcl-xl抑制剂中的用途 |
| PY24103486A (es) | 2023-11-22 | 2025-06-06 | Servier Lab | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos |
| TW202540186A (zh) | 2023-11-22 | 2025-10-16 | 瑞士商諾華公司 | 抗ｃｄ７抗體藥物結合物及其使用方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2251419C2 (ru) * | 2000-06-21 | 2005-05-10 | Ф. Хоффманн-Ля Рош Аг | Производные бензотиазола |
| WO2010080503A1 (en) * | 2008-12-19 | 2010-07-15 | Genentech, Inc. | Heterocyclic compounds and methods of use |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| PT1019385E (pt) | 1995-09-15 | 2004-06-30 | Upjohn Co | N-oxidos de aminoaril-oxazolidinona |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| CA2508947A1 (en) | 2002-12-20 | 2004-07-15 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| PL1737850T3 (pl) | 2004-04-19 | 2008-02-29 | Symed Labs Ltd | Nowy sposób wytwarzania linezolidu i związków pokrewnych |
| WO2006008754A1 (en) | 2004-07-20 | 2006-01-26 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
| EP1804823A4 (en) | 2004-09-29 | 2010-06-09 | Amr Technology Inc | NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| MX2009008465A (es) | 2007-02-15 | 2009-08-20 | Hoffmann La Roche | Nuevas 2-aminooxazolinas como ligandos de taar1. |
| KR20100105802A (ko) | 2007-04-19 | 2010-09-29 | 콘서트 파마슈티컬즈, 인크. | 중수소화된 모르폴리닐 화합물 |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| US20090137457A1 (en) | 2007-10-02 | 2009-05-28 | Concert Pharmaceuticals, Inc. | Pyrimidinedione derivatives |
| EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| AU2008317375B2 (en) | 2007-10-26 | 2013-02-28 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| NZ593536A (en) * | 2008-12-19 | 2013-07-26 | Genentech Inc | Quinoline derivatives and methods of use |
| KR20110123657A (ko) * | 2010-05-07 | 2011-11-15 | 에스케이케미칼주식회사 | 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
| TWI561521B (en) * | 2011-10-14 | 2016-12-11 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
-
2012
- 2012-10-08 TW TW101137131A patent/TWI571466B/zh not_active IP Right Cessation
- 2012-10-10 UY UY0001034382A patent/UY34382A/es unknown
- 2012-10-11 DK DK12780605.7T patent/DK2766361T3/en active
- 2012-10-11 SG SG11201401279XA patent/SG11201401279XA/en unknown
- 2012-10-11 CR CR20200097A patent/CR20200097A/es unknown
- 2012-10-11 RU RU2014119250A patent/RU2625315C2/ru active
- 2012-10-11 EP EP12780605.7A patent/EP2766361B1/en active Active
- 2012-10-11 CA CA2851364A patent/CA2851364C/en active Active
- 2012-10-11 PH PH1/2014/500729A patent/PH12014500729A1/en unknown
- 2012-10-11 UA UAA201405089A patent/UA115042C2/uk unknown
- 2012-10-11 AU AU2012322698A patent/AU2012322698A1/en not_active Abandoned
- 2012-10-11 MY MYPI2014700867A patent/MY172723A/en unknown
- 2012-10-11 ME MEP-2016-227A patent/ME02514B/me unknown
- 2012-10-11 HR HRP20161319TT patent/HRP20161319T1/hr unknown
- 2012-10-11 JP JP2014535869A patent/JP6155270B2/ja active Active
- 2012-10-11 WO PCT/US2012/059720 patent/WO2013055897A1/en not_active Ceased
- 2012-10-11 PE PE2014000506A patent/PE20141282A1/es active IP Right Grant
- 2012-10-11 PL PL12780605T patent/PL2766361T3/pl unknown
- 2012-10-11 BR BR112014009053-0A patent/BR112014009053B1/pt not_active IP Right Cessation
- 2012-10-11 ES ES12780605.7T patent/ES2598877T3/es active Active
- 2012-10-11 HU HUE12780605A patent/HUE030589T2/en unknown
- 2012-10-11 RS RS20160954A patent/RS55342B1/sr unknown
- 2012-10-11 KR KR1020147012846A patent/KR102019643B1/ko not_active Expired - Fee Related
- 2012-10-11 MX MX2014004556A patent/MX356031B/es active IP Right Grant
- 2012-10-11 PT PT127806057T patent/PT2766361T/pt unknown
- 2012-10-11 SI SI201230730A patent/SI2766361T1/sl unknown
- 2012-10-11 LT LTEP12780605.7T patent/LT2766361T/lt unknown
- 2012-10-12 AR ARP120103811A patent/AR088327A1/es active IP Right Grant
-
2014
- 2014-04-01 IL IL231856A patent/IL231856A/en active IP Right Grant
- 2014-04-08 ZA ZA2014/02556A patent/ZA201402556B/en unknown
- 2014-04-09 DO DO2014000070A patent/DOP2014000070A/es unknown
- 2014-04-10 CL CL2014000905A patent/CL2014000905A1/es unknown
- 2014-04-10 GT GT201400064A patent/GT201400064A/es unknown
- 2014-05-06 CR CR20140205A patent/CR20140205A/es unknown
- 2014-05-07 CO CO14097093A patent/CO6950476A2/es unknown
- 2014-05-08 EC ECIEPI2014357A patent/ECSP14000357A/es unknown
-
2015
- 2015-06-30 PH PH12015501498A patent/PH12015501498B1/en unknown
-
2016
- 2016-10-27 CY CY20161101096T patent/CY1118224T1/el unknown
-
2017
- 2017-04-19 JP JP2017082912A patent/JP6395893B2/ja active Active
- 2017-07-20 AU AU2017206246A patent/AU2017206246B2/en not_active Ceased
-
2019
- 2019-02-01 DO DO2019000022A patent/DOP2019000022A/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2251419C2 (ru) * | 2000-06-21 | 2005-05-10 | Ф. Хоффманн-Ля Рош Аг | Производные бензотиазола |
| WO2010080503A1 (en) * | 2008-12-19 | 2010-07-15 | Genentech, Inc. | Heterocyclic compounds and methods of use |
Non-Patent Citations (1)
| Title |
|---|
| Sarah Barelier et al: ";Fragment-Based Deconstruction of Bcl-xL Inhibitors";, Journal of medicinal chemistry, 53(6), 2010, c.2577-2588. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2857201C2 (ru) * | 2020-06-01 | 2026-02-27 | Виген Биомедисн Текнолоджи (Шанхай) Ко., Лтд. | Новое соединение пиразина |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11786519B2 (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| JP6395893B2 (ja) | 癌ならびに免疫疾患および自己免疫疾患の治療のためのアポトーシス誘発剤としての８−カルバモイル−２−（２，３−ジ置換ピリド−６−イル）−１，２，３，４−テトラヒドロイソキノリン誘導体 | |
| TWI634118B (zh) | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘導劑 | |
| ES2699966T3 (es) | Agentes inductores de la apoptosis para el tratamiento del cáncer y enfermedades inmunes y autoinmunes | |
| ES2544452T3 (es) | Compuestos heterocíclicos y métodos de uso | |
| HK1200167B (en) | 8-carbamoyl-2-(2,3-disubstituted pyrid-6-yl)-1,2,3,4-tetrahydroisoquinoline derivatives as apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| NZ623100B2 (en) | 8 - carbamoyl - 2 - (2,3- di substituted pyrid - 6 - yl) -1,2,3,4 -tetrahydroisoquinoline derivatives as apoptosis - inducing agents for the treatment of cancer and immune and autoimmune diseases |